- Allergy Therapeutics said Thursday it expected that full-year revenues and expenses would be in-line with market expectations amid 'strong' performance in an 'unusually weak' pollen season.

For the year ended 30 June 2018, reported revenues are expected to come in at £68.3m, up 6.6% from £64.1m the previous year.

The company said it gained a 0.7 market share point within its core markets in Europe.

The cash balance at the end of June 2018 was £15.5m compared with £22.1m the previous year.

The ongoing pipeline trials continued to progress well, and the company remained on track to deliver the results of the pivotal Birch Phase III trial for Europe in the third quarter of 2018.

At 9:54am: [LON:AGY] Allergy Therapeutics PLC share price was 0p at 28.25p

Story provided by